# DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients

> **NCT00107614** · PHASE2 · TERMINATED · sponsor: **University of Arkansas** · enrollment: 12 (actual)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** DT PACE + Rituxan

## Key facts

- **NCT ID:** NCT00107614
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-11
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Terminated due to poor accrual.
- **Last updated:** 2011-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107614, "DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00107614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*